Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
204 hedge funds and large institutions have $2.36B invested in Portola Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 72 increasing their positions, 54 reducing their positions, and 21 closing their positions.
114% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 21
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
33% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 54
27% more capital invested
Capital invested by funds: $1.86B → $2.36B (+$497M)
13% more funds holding
Funds holding: 180 → 204 (+24)
22% less call options, than puts
Call options by funds: $20.7M | Put options by funds: $26.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$55.3M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$39.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$24.9M |
| 4 |
BlackRock
New York
|
+$22.3M |
| 5 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$17.2M |
| 2 |
D.E. Shaw & Co
New York
|
-$15M |
| 3 |
PA
Perceptive Advisors
New York
|
-$14.4M |
| 4 |
Renaissance Technologies
New York
|
-$12M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.44M |
PTLA Hedge Fund Activity: Q2 2018 in Review
204 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2018, worth a combined $2.36B — up 27% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PTLA positions and 21 closed out — a net gain of 24 holders — while 72 added to existing stakes and 54 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $55.3M. The largest seller was Deutsche Bank, cutting an estimated $17.2M.
- 204 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2018, up from 180 in Q1 2018.
- Funds reported $2.36B of Portola Pharmaceuticals, Inc. stock for Q2 2018, up 27% quarter-over-quarter.
- 45 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2018 and 21 closed out, a net change of +24 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q2 2018 was Deerfield Management, an estimated $55.3M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q2 2018 was Deutsche Bank, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2018.